Literature DB >> 24227843

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.

Adeline Heurich1, Heike Hofmann-Winkler, Stefanie Gierer, Thomas Liepold, Olaf Jahn, Stefan Pöhlmann.   

Abstract

The type II transmembrane serine proteases TMPRSS2 and HAT can cleave and activate the spike protein (S) of the severe acute respiratory syndrome coronavirus (SARS-CoV) for membrane fusion. In addition, these proteases cleave the viral receptor, the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), and it was proposed that ACE2 cleavage augments viral infectivity. However, no mechanistic insights into this process were obtained and the relevance of ACE2 cleavage for SARS-CoV S protein (SARS-S) activation has not been determined. Here, we show that arginine and lysine residues within ACE2 amino acids 697 to 716 are essential for cleavage by TMPRSS2 and HAT and that ACE2 processing is required for augmentation of SARS-S-driven entry by these proteases. In contrast, ACE2 cleavage was dispensable for activation of the viral S protein. Expression of TMPRSS2 increased cellular uptake of soluble SARS-S, suggesting that protease-dependent augmentation of viral entry might be due to increased uptake of virions into target cells. Finally, TMPRSS2 was found to compete with the metalloprotease ADAM17 for ACE2 processing, but only cleavage by TMPRSS2 resulted in augmented SARS-S-driven entry. Collectively, our results in conjunction with those of previous studies indicate that TMPRSS2 and potentially related proteases promote SARS-CoV entry by two separate mechanisms: ACE2 cleavage, which might promote viral uptake, and SARS-S cleavage, which activates the S protein for membrane fusion. These observations have interesting implications for the development of novel therapeutics. In addition, they should spur efforts to determine whether receptor cleavage promotes entry of other coronaviruses, which use peptidases as entry receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24227843      PMCID: PMC3911672          DOI: 10.1128/JVI.02202-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium.

Authors:  Eva Böttcher; Tatyana Matrosovich; Michaela Beyerle; Hans-Dieter Klenk; Wolfgang Garten; Mikhail Matrosovich
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Proteolytic activation of the 1918 influenza virus hemagglutinin.

Authors:  Chawaree Chaipan; Darwyn Kobasa; Stephanie Bertram; Ilona Glowacka; Imke Steffen; Theodros Solomon Tsegaye; Makoto Takeda; Thomas H Bugge; Semi Kim; Youngwoo Park; Andrea Marzi; Stefan Pöhlmann
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

3.  Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Authors:  Heike Hofmann; Krzysztof Pyrc; Lia van der Hoek; Martina Geier; Ben Berkhout; Stefan Pöhlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

4.  Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2.

Authors:  Yuta Shirogane; Makoto Takeda; Masaharu Iwasaki; Nobuhisa Ishiguro; Hiroki Takeuchi; Yuichiro Nakatsu; Maino Tahara; Hideaki Kikuta; Yusuke Yanagi
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

5.  Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63.

Authors:  Ilona Glowacka; Stephanie Bertram; Petra Herzog; Susanne Pfefferle; Imke Steffen; Marcus O Muench; Graham Simmons; Heike Hofmann; Thomas Kuri; Friedemann Weber; Jutta Eichler; Christian Drosten; Stefan Pöhlmann
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

6.  Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme.

Authors:  Michikado Iwata; Jorge E Silva Enciso; Barry H Greenberg
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-16       Impact factor: 4.249

7.  Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia.

Authors:  Hong Peng Jia; Dwight C Look; Ping Tan; Lei Shi; Melissa Hickey; Lokesh Gakhar; Mark C Chappell; Christine Wohlford-Lenane; Paul B McCray
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-01       Impact factor: 5.464

8.  TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds.

Authors:  Shiori Haga; Noriyo Nagata; Tadashi Okamura; Norio Yamamoto; Tetsutaro Sata; Naoki Yamamoto; Takehiko Sasazuki; Yukihito Ishizaka
Journal:  Antiviral Res       Date:  2009-12-06       Impact factor: 5.970

9.  SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells.

Authors:  Eric C Mossel; Jieru Wang; Scott Jeffers; Karen E Edeen; Shuanglin Wang; Gregory P Cosgrove; C Joel Funk; Rizwan Manzer; Tanya A Miura; Leonard D Pearson; Kathryn V Holmes; Robert J Mason
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

10.  Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.

Authors:  Geoffrey J Gorse; Theresa Z O'Connor; Susan L Hall; Joseph N Vitale; Kristin L Nichol
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

View more
  325 in total

1.  Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains.

Authors:  James T Earnest; Michael P Hantak; Jung-Eun Park; Tom Gallagher
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

2.  Neurovirulent Murine Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry and Cell-Cell Fusion.

Authors:  Judith M Phillips; Tom Gallagher; Susan R Weiss
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  Cardiovascular Complications of COVID-19 and Associated Concerns: A Review.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

Review 4.  Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Henok Kessete Afewerky
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-07

5.  DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry.

Authors:  Pawel Zmora; Paulina Blazejewska; Anna-Sophie Moldenhauer; Kathrin Welsch; Inga Nehlmeier; Qingyu Wu; Heike Schneider; Stefan Pöhlmann; Stephanie Bertram
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  TMPRSS12 Is an Activating Protease for Subtype B Avian Metapneumovirus.

Authors:  Bingling Yun; Yao Zhang; Yongzhen Liu; Xiaolu Guan; Yongqiang Wang; Xiaole Qi; Hongyu Cui; Changjun Liu; Yanping Zhang; Honglei Gao; Li Gao; Kai Li; Yulong Gao; Xiaomei Wang
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

8.  Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection.

Authors:  Arlene Barlan; Jincun Zhao; Mayukh K Sarkar; Kun Li; Paul B McCray; Stanley Perlman; Tom Gallagher
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

9.  Modulation of CD163 expression by metalloprotease ADAM17 regulates porcine reproductive and respiratory syndrome virus entry.

Authors:  Longjun Guo; Junwei Niu; Haidong Yu; Weihong Gu; Ren Li; Xiaolei Luo; Mingming Huang; Zhijun Tian; Li Feng; Yue Wang
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

Review 10.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.